不良研究所

Home

听

The Neuro is patient care, Open Science research and training.

Order of Canada is bestowed on Dr. Guy Rouleau

Published: 27 November 2020

Doctor has dedicated his life to improve diagnosis and treatment of neurological diseases and disorders...

The MNI forms promising Open Science partnership with Takeda

Published: 4 December 2017

Industry and academia team up for the benefit of people suffering from ALS...

An exceptional donation to support autism research

Published: 13 November 2019

Q1K: A collaborative undertaking involving 1,000听families to transform autism care

Gairdner Foundation recognizes Dr. Guy Rouleau with prestigious award

Published: 31 March 2020

The Neuro鈥檚 director has been a driving force in neurological disease research and Open Science leadership

My journey to open science

1 Apr 2020

Because it accelerates discovery, Open Science is vital to finding new ways to help our patients

Gairdner Foundation recognizes Dr. Guy Rouleau with prestigious award

31 Mar 2020

The Neuro鈥檚 director has been a driving force in neurological disease research and Open Science leadership

Discovering innovative ways to address autism

17 Jan 2020

Healthcare that is informed by research and patient insights is the most effective way to advance knowledge

Major ALS Research Funding Announced

Published: 23 November 2016

MNI scientists will study stem cells, genetic mutations to develop new treatments...

The Neuro to create world鈥檚 first ALS Phase 1 clinical trial unit

Published: 3 July 2017

The Tenaquip Foundation donation will allow for faster drug development, better care for ALS patients...

Pages

Subscribe to Guy Rouleau RSS

The Neuro logo听不良研究所 logo

听

The Neuro (Montreal Neurological Institute-Hospital)听is a bilingual academic healthcare institution. We are a听不良研究所 research and teaching institute; delivering high-quality patient care, as part of the Neuroscience Mission of the 不良研究所 Health Centre.听We are听proud to be a Killam Institution, supported by the Killam Trusts.

听

听

Back to top